Prime Medicine (PRME) News Today $1.46 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.49 +0.03 (+2.05%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of StockJune 13 at 8:44 AM | insidertrades.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in StockPrime Medicine, Inc. (NYSE:PRME - Get Free Report) major shareholder David R. Liu bought 21,000 shares of the stock in a transaction on Wednesday, June 11th. The stock was purchased at an average cost of $1.60 per share, for a total transaction of $33,600.00. Following the acquisition, the insider now directly owns 20,177,945 shares of the company's stock, valued at $32,284,712. The trade was a 0.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.June 12 at 5:38 PM | marketbeat.comTwo Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)Two Sigma Investments LP decreased its stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 47.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 166,199 shares of the company's stock after selling 152,374 sharesJune 10, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Prime Medicine, Inc. (NYSE:PRME - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, four have issued a buy recommendation aJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)Millennium Management LLC lowered its stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,874,571 shares of the company's stoMay 30, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comPrime Medicine's (PRME) "Neutral" Rating Reaffirmed at CitigroupCitigroup reissued a "neutral" rating and set a $1.50 target price (down previously from $10.00) on shares of Prime Medicine in a research report on Tuesday.May 28, 2025 | marketbeat.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.comChardan Capital Raises Earnings Estimates for Prime MedicinePrime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Chardan Capital boosted their FY2025 earnings per share (EPS) estimates for shares of Prime Medicine in a note issued to investors on Tuesday, May 20th. Chardan Capital analyst G. Livshits now anticipates that the company willMay 25, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Prime MedicinePrime Medicine, Inc. (NYSE:PRME - Free Report) - Investment analysts at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for Prime Medicine in a report released on Tuesday, May 20th. HC Wainwright analyst A. He now anticipates that the company will earn ($0.85) per share forMay 24, 2025 | marketbeat.comWedbush Has Bullish Estimate for Prime Medicine Q3 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at Wedbush lifted their Q3 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a report released on Monday, May 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per sMay 23, 2025 | marketbeat.comWestwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)Westwood Holdings Group Inc. lifted its stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 96.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 883,129 shares of the company's stock after purchasing an additional 433,653May 23, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Downgraded to "Neutral" Rating by HC WainwrightHC Wainwright lowered shares of Prime Medicine from a "buy" rating to a "neutral" rating in a research note on Tuesday.May 22, 2025 | marketbeat.comPrime Medicine's (PRME) Neutral Rating Reaffirmed at JPMorgan Chase & Co.JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Prime Medicine in a report on Tuesday.May 22, 2025 | marketbeat.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21, 2025 | nasdaq.comPrime Medicine drops after cutting CGD program amid restructuringMay 20, 2025 | msn.comPrime Medicine stock plummets amid restructuring and leadership changesMay 20, 2025 | msn.comPrime Medicine Announces Layoffs, CEO Transition: Retail Gets More BullishMay 20, 2025 | msn.comPrime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term VolatilityMay 19, 2025 | tipranks.comPrime Medicine Appoints New CEO Amid RestructuringMay 19, 2025 | tipranks.comPrime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership TransitionMay 19, 2025 | globenewswire.comPrime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous DiseaseMay 19, 2025 | globenewswire.comPrime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a BuyMay 13, 2025 | tipranks.comAnalysts Offer Predictions for Prime Medicine Q1 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings per share estimates for Prime Medicine in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.38) per share for thMay 13, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Average Recommendation of "Buy" by AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy ratiMay 12, 2025 | marketbeat.comPRIME MEDICINE Earnings Preview: Recent $PRME Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comPrime Medicine Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 8, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)T. Rowe Price Investment Management Inc. lifted its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,977,828 shares of the company's stock afApril 30, 2025 | marketbeat.comPrime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359April 26, 2025 | seekingalpha.comPrime Medicine, Inc. (NYSE:PRME) Shares Bought by Walleye Capital LLCWalleye Capital LLC raised its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 272.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 403,739 shares of the company's stock afApril 22, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by AnalystsPrime Medicine, Inc. (NYSE:PRME - Get Free Report) has been given an average recommendation of "Buy" by the nine ratings firms that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. TheApril 16, 2025 | marketbeat.comPrime Medicine Stock Price, Quotes and ForecastsApril 13, 2025 | benzinga.comWedbush Forecasts Prime Medicine FY2029 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Wedbush issued their FY2029 earnings per share estimates for Prime Medicine in a report released on Tuesday, March 18th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($1.27) per share for the year. WedMarch 22, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Expected to Rise, Chardan Capital Analyst SaysChardan Capital upped their target price on shares of Prime Medicine from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday.March 21, 2025 | marketbeat.comPrime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine's (PRME) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Prime Medicine in a research note on Wednesday.March 20, 2025 | marketbeat.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushWedbush restated an "outperform" rating and issued a $13.00 target price (up from $12.00) on shares of Prime Medicine in a research note on Tuesday.March 19, 2025 | marketbeat.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comPrime Medicine unveils program for treatment of AATDMarch 18, 2025 | markets.businessinsider.comPrime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy RatingMarch 18, 2025 | tipranks.comPrime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)March 18, 2025 | globenewswire.comPrime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy RatingMarch 18, 2025 | tipranks.comChardan Capital Estimates Prime Medicine FY2025 EarningsPrime Medicine, Inc. (NYSE:PRME - Free Report) - Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Prime Medicine in a research report issued to clients and investors on Monday, March 10th. Chardan Capital analyst G. Livshits expects that the company will post earnings peMarch 14, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Releases Quarterly Earnings ResultsPrime Medicine (NYSE:PRME - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($1.65) earnings per share for the quarter.March 8, 2025 | marketbeat.comQ1 EPS Estimates for Prime Medicine Lifted by HC WainwrightPrime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Prime Medicine in a research note issued on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($March 7, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)March 4, 2025 | markets.businessinsider.com Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼1.630.89▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼43▲PRME Articles Average Week Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Oculis News Zymeworks News Intellia Therapeutics News Nuvation Bio News ArriVent BioPharma News Immunome News Pharming Group News Chimerix News Avid Bioservices News Gyre Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRME Stock Free PRME Stock Alerts